HC Wainwright Reaffirms Buy Rating for Celcuity (NASDAQ:CELC)

Celcuity (NASDAQ:CELC)‘s stock had its “buy” rating reissued by investment analysts at HC Wainwright in a research note issued to investors on Friday,Benzinga reports. They currently have a $155.00 price objective on the stock. HC Wainwright’s price target points to a potential upside of 68.46% from the company’s current price.

CELC has been the topic of a number of other research reports. Citizens Jmp boosted their target price on Celcuity from $160.00 to $177.00 and gave the stock a “market outperform” rating in a research note on Wednesday, July 15th. Weiss Ratings raised Celcuity from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, June 4th. Wells Fargo & Company dropped their price target on Celcuity from $183.00 to $166.00 and set an “overweight” rating on the stock in a report on Wednesday, June 3rd. Craig Hallum restated a “buy” rating and issued a $178.00 price objective on shares of Celcuity in a research note on Wednesday, July 15th. Finally, Wall Street Zen cut Celcuity from a “hold” rating to a “sell” rating in a research note on Saturday, April 25th. Ten analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Celcuity currently has an average rating of “Moderate Buy” and an average target price of $153.64.

Celcuity Stock Up 6.2%

Shares of CELC traded up $5.41 during trading hours on Friday, reaching $92.01. 844,880 shares of the stock traded hands, compared to its average volume of 1,111,195. Celcuity has a 52 week low of $44.42 and a 52 week high of $151.02. The company has a market cap of $4.49 billion, a price-to-earnings ratio of -23.70 and a beta of 0.20. The stock has a fifty day simple moving average of $93.81 and a 200 day simple moving average of $108.56. The company has a current ratio of 12.31, a quick ratio of 12.31 and a debt-to-equity ratio of 6.04.

Celcuity (NASDAQ:CELC) last issued its quarterly earnings data on Thursday, August 13th. The company reported ($1.44) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.16) by ($0.28). The business had revenue of $0.09 million for the quarter, compared to analyst estimates of $4.42 million. On average, equities analysts forecast that Celcuity will post -3.76 EPS for the current year.

Institutional Trading of Celcuity

Several hedge funds have recently made changes to their positions in CELC. EverSource Wealth Advisors LLC lifted its position in shares of Celcuity by 1,329.2% during the 4th quarter. EverSource Wealth Advisors LLC now owns 343 shares of the company’s stock valued at $34,000 after buying an additional 319 shares during the last quarter. US Bancorp DE raised its position in shares of Celcuity by 25.4% in the third quarter. US Bancorp DE now owns 706 shares of the company’s stock valued at $35,000 after purchasing an additional 143 shares during the period. BNP Paribas Financial Markets lifted its stake in shares of Celcuity by 78.9% during the 2nd quarter. BNP Paribas Financial Markets now owns 2,647 shares of the company’s stock valued at $35,000 after buying an additional 1,167 shares in the last quarter. Parallel Advisors LLC purchased a new stake in shares of Celcuity during the 1st quarter valued at approximately $38,000. Finally, Meeder Asset Management Inc. purchased a new position in Celcuity in the 4th quarter valued at approximately $42,000. 63.33% of the stock is currently owned by institutional investors.

Celcuity News Roundup

Here are the key news stories impacting Celcuity this week:

• Positive Sentiment: Celcuity’s REVTORPYK (gedatolisib) received FDA approval and was rapidly included in the NCCN Category 1 guidelines, potentially accelerating physician adoption and reducing commercialization risk. Data from the VIKTORIA-1 trial showed strong efficacy and tolerability, supporting expectations that the therapy could become a blockbuster product. Celcuity: REVTORPYK Is Now A Commercial Story
• Positive Sentiment: The company ended the quarter with approximately $754 million in cash, providing funding visibility into 2029 despite increased commercial spending. This liquidity reduces near-term financing risk as Celcuity launches REVTORPYK. Celcuity Second-Quarter 2026 Results
• Neutral Sentiment: Stifel lowered its price target from $175 to $150, while Needham reduced its target from $157 to $140. Both firms maintained Buy ratings, indicating reduced near-term estimates but continued confidence in the long-term opportunity. Needham Lowers Celcuity Price Target
• Negative Sentiment: Second-quarter results highlighted the costs and execution risk of the launch. Celcuity reported a loss of $1.44 per share versus the $1.16 consensus estimate, while revenue of $0.09 million fell far short of the $4.42 million expectation. Analysts subsequently cut their forecasts, and selling, general and administrative expenses are expected to rise as commercialization accelerates. Celcuity Analysts Cut Forecasts

About Celcuity

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.